Related Party Transactions

Series G Redeemable Convertible Preferred Stock Financing

On January 30, 2018 and on February 15, 2018, respectively, we entered into Series G Preferred Stock Purchase Agreements, pursuant to which we issued and sold an aggregate of 55,666,004 shares of our Series G redeemable convertible preferred stock at a price per share of $10.06, for an aggregate purchase price of $560.0 million. The following table sets forth the number of shares of our Series G redeemable convertible preferred stock that we issued to our related parties in this transaction (in thousands, except share data):



Name	Shares of Series G Redeemable Convertible Preferred Stock	Total Purchase Price
OCHA LLC⁽¹⁾	50,000	$	503
Viking Global Investors LP and affiliated entities⁽²⁾	745,526	$	7,500

______


⁽¹⁾	OCHA LLC is an entity controlled by an officer.

⁽²⁾

Consists of (1) 279,160 shares of Series G redeemable convertible preferred stock held by VGE III Portfolio Ltd.; (2) 148,974 shares of Series G preferred stock held by Viking Global Equities LP; (3) 8,737 shares of Series G redeemable convertible preferred stock held by Viking Global Equities II LP; (4) 129,537 shares of Series G preferred stock held by Viking Global Opportunities Illiquid Investments Sub-Master LP; and (5) 179,118 shares of Series G redeemable convertible preferred stock held by Viking Long Fund Master Ltd.

Other Transactions

The following is a description of additional transactions we have engaged in for the years ended December 31, 2019, 2018 and 2017, with our related parties.

One of our former board members served as Senior Counsel at Covington & Burling LLP (Covington). We paid Covington approximately $0.1 million, $0.2 million and $0.2 million for legal services for the year ended December 31, 2019, 2018 and 2017, respectively. We had no outstanding accounts payable balances to Covington at December 31, 2019 and 2018.

AstraZeneca is considered to be a related party due to its equity ownership in us. We have also entered into strategic alliances with AstraZeneca. For the years ended December 31, 2019, 2018 and 2017, we received payments of $7.9 million, $34.0 million and $1.1 million, respectively. At December 31, 2019 and 2018, our outstanding accounts receivable balances from AstraZeneca were $0.3 million and $0.9 million, respectively. Refer to Note 3 for a discussion of the strategic alliances and related transaction.